1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Pulmicort (Asthma) - Forecast and Market Analysis to 2023

Pulmicort (Asthma) - Forecast and Market Analysis to 2023


GlobalData has released its new PharmaPoint Drug Evaluation report, “Pulmicort (Asthma) - Forecast and Market Analysis to 2023”. The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

AstraZeneca’s Pulmicort is an ICS therapy that was originally launched in 1997, and is used prophylactically for the maintenance treatment of asthma in children and adults. Its active ingredient, budesonide, is an anti-inflammatory corticosteroid with a high affinity for the corticosteroid receptor. AstraZeneca’s Pulmicort franchise includes the Pulmicort Flexhaler (budesonide) for adults and pediatric patients older than six years of age, Pulmicort Respules for children between one and eight years of age, and the Pulmicort Turbuhaler for patients with bronchial asthma.


- Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Pulmicort including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Pulmicort for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Asthma
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Pulmicort performance
- Obtain sales forecast for Pulmicort from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table Of Contents

Pulmicort (Asthma) - Forecast and Market Analysis to 2023
1 Table of Contents

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 12
3.1.3 Prognosis 15
3.1.4 Quality of Life 15
3.2 Symptoms 16
4 Disease Management 17
4.1 Diagnosis and Treatment Overview 17
4.1.1 Diagnosis 17
4.1.2 Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs 18
4.1.3 Clinical Practice 20
5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 27
6 Pulmicort (budesonide) 31
6.1 Overview 31
6.2 Efficacy 33
6.3 Safety 34
6.4 SWOT Analysis 35
6.5 Forecast 35
7 Appendix 37
7.1 Bibliography 37
7.2 Abbreviations 40
7.3 Methodology 43
7.4 Forecasting Methodology 43
7.4.1 Diagnosed Asthma Patients 43
7.4.2 Percent Drug-Treated Patients 44
7.4.3 General Pricing Assumptions 44
7.4.4 Individual Drug Assumptions 45
7.4.5 Generic Erosion 45
7.5 Physicians and Specialists Included in This Study 46
7.6 About the Authors 49
7.6.1 Author 49
7.6.2 Author/Reviewer 49
7.6.3 Reviewer 50
7.6.4 Global Head of Healthcare 51
7.7 About GlobalData 52
7.8 Disclaimer 52

1.1 List of Tables

Table 1: Symptoms of Asthma 16
Table 2: Treatment Guidelines for Asthma by Country 18
Table 3: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013 19
Table 4: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency 22
Table 5: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age 24
Table 6: Leading Treatments for Asthma, 2014 30
Table 7: Product Profile - Pulmicort 32
Table 8: Pulmicort-Associated Adverse Events 34
Table 9: Pulmicort SWOT Analysis, 2014 35
Table 10: Global Sales Forecast ($) for Pulmicort, 2013-2023 36
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 48

1.2 List of Figures

Figure 1:Stepwise Disease Management Approach for Asthma in Adults 21
Figure 2: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hepatitis C: KOL Insight

Hepatitis C: KOL Insight

  • $ 8 085
  • Industry report
  • September 2016
  • by Firstword Pharma

As hepatitis C cures multiply, how do experts evaluate the options? Since the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace. The focus ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 8 085
  • Industry report
  • August 2016
  • by Firstword Pharma

How will established and emerging agents reshape the CLL treatment landscape? How do key opinion leaders (KOLs) see the future treatment paradigm for chronic lymphocytic leukaemia (CLL) shaping up? Will ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Download Unlimited Documents from Trusted Public Sources

Therapy Market in Denmark

  • October 2016
    11 pages
  • Therapy  


  • Denmark  

View report >

Therapy Market in Denmark

  • October 2016
    11 pages
  • Therapy  


  • Denmark  

View report >

Opioid Market in the US

  • October 2016
    32 pages
  • Opioid  


    Infectious Dise...  

  • United States  



View report >

Related Market Segments :



Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.